Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
Authors not listed
Neurogen Biomarking LLC · 2025
Abstract
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2025). Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device. <em>Neurogen Biomarking LLC</em>. https://clinicaltrials.gov/study/NCT07701161
Vancouver
Anonymous. Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device. Neurogen Biomarking LLC. 2025.
BibTeX
@misc{anon2025Develo,
title = {Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device},
author = {Anonymous},
journal = {Neurogen Biomarking LLC},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Columbia University 2019
Open access · US-GOV
Autoimmune Features of Neurodegenerative Disorders
University of Kansas Medical Center 2019
Open access · US-GOV
Enhanced Mediterranean Diet for Alzheimer's Disease Prevention
University of Colorado, Denver 2016
Open access · US-GOV
Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment
The Lancet 2021
Preprint · OA
Alzheimer's disease
Handbook of clinical neurology 2019
Citation only
Alzheimer's disease
Pfizer 2009
Open access · US-GOV